公开(公告)号：WO2019064304A1

公开(公告)日：2019-04-04

申请号：PCT/IL2018/051072

申请日：2018-09-27

Applicant: YAYON, Avner ,  ROM, Eran

Inventor： YAYON, Avner ,  ROM, Eran

IPC: A61K39/395 ,  A61P25/00

CPC classification number: A61P25/00 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/2863 ,  C07K2317/33 ,  C07K2317/622 ,  C07K2317/92

Abstract: The present invention relates to compositions and methods of treating multiple sclerosis. Particularly, the present invention relates to pharmaceutical compositions comprising antibodies having affinity to both fibroblast growth factor receptor 2 (FGFR2) and FGFR3 for use in treating multiple sclerosis.

公开(公告)号：WO2018095932A1

公开(公告)日：2018-05-31

申请号：PCT/EP2017/079976

申请日：2017-11-21

Applicant: MERCK PATENT GMBH

Inventor： IFFLAND, Christel ,  ESDAR, Christina ,  ZHAO, Xinyan ,  AN, Qi ,  YEH, Johannes ,  HAO, Gang ,  TOLEIKIS, Lars ,  SOOD, Vanita ,  NANNEMANN, David ,  LYTLE, Robin ,  HOCK, Bjoern

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.

公开(公告)号：WO2018093866A1

公开(公告)日：2018-05-24

申请号：PCT/US2017061757

申请日：2017-11-15

Applicant: REGENERON PHARMA

Inventor： BABB ROBERT ,  CHEN GANG ,  DALY CHRISTOPHER ,  DASILVA JOHN ,  MACDONALD DOUGLAS

IPC: C07K16/28 ,  A61K47/68

CPC classification number: C07K16/2863 ,  A61K31/537 ,  A61K47/6803 ,  A61K47/6849 ,  A61K47/6857 ,  A61K47/6863 ,  A61P35/00 ,  C07K16/3023 ,  C07K16/3046 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are antibodies and bispecific antigen-binding molecules that bind MET and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human MET. The bispecific antigen-binding molecules are capable of blocking the interaction between human MET and its ligand HGF. The bispecific antigen-binding molecules can exhibit minimal or no MET agonist activity, e.g., as compared to monovalent antigen-binding molecules that comprise only one of the antigen-binding domains of the bispecific molecule, which tend to exert unwanted MET agonist activity. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.

公开(公告)号：WO2018075304A1

公开(公告)日：2018-04-26

申请号：PCT/US2017/056052

申请日：2017-10-11

Applicant: ELI LILLY AND COMPANY

Inventor： BURTRUM, Douglas, Bryan ,  DRISCOLL, Kyla, Elizabeth

IPC: A61K39/395 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K39/39541 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2827 ,  C07K16/2866 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to antibodies that bind TGFβ receptor II (TGFβRII), and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.

Abstract translation: 本发明涉及结合TGFβ受体II（TGFβRII）的抗体，并且可用于单独治疗癌症以及与化疗和其它癌症治疗剂组合。

公开(公告)号：WO2017201166A1

公开(公告)日：2017-11-23

申请号：PCT/US2017/033112

申请日：2017-05-17

Applicant: DUKE UNIVERSITY

Inventor： NIXON, Andrew ,  BRADY, Chris ,  LIU, Yingmiao ,  HURWITZ, Herbert ,  OWZAR, Kouros ,  SIBLEY, Alexander ,  JIANG, Chen ,  HATCH, Ace ,  STARR, Mark

IPC: A61K31/7068 ,  A61K39/395 ,  C07K16/22 ,  C12Q1/68 ,  G01N33/574

CPC classification number: G01N33/57419 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/55 ,  A61P35/00 ,  C07K16/22 ,  C07K16/2863 ,  C07K2317/24 ,  C07K2317/76 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2800/52 ,  A61K2300/00

Abstract: Methods of predicting responsiveness of a cancer in a subject to a cancer therapy including a VEGF targeting agent are provided. The methods may include obtaining a sample from the subject, determining an expression level of at least one biomarker selected from the group consisting of VEGF-D and PIGF in a sample from the subject, comparing the expression level of the biomarker in the sample to a reference level of the biomarker, and predicting the responsiveness of the cancer to treatment with the cancer therapy including a VEGF targeting agent. Optionally, the methods may further include administering a VEGF target agent and/or an anticancer or chemotherapy agent to the subject. Additional methods of prognosing and treating a cancer in a subject are also provided.

Abstract translation: 提供了预测受试者中的癌症对包括VEGF靶向剂的癌症疗法的响应性的方法。 所述方法可包括从受试者获得样品，确定来自受试者的样品中选自VEGF-D和PIGF的至少一种生物标志物的表达水平，将样品中生物标志物的表达水平与 生物标志物的参考水平，并且预测癌症对包括VEGF靶向剂的癌症治疗的治疗的响应性。 任选地，所述方法可以进一步包括向所述受试者施用VEGF靶剂和/或抗癌剂或化疗剂。 还提供了预测和治疗受试者癌症的其他方法。

公开(公告)号：WO2017162733A1

公开(公告)日：2017-09-28

申请号：PCT/EP2017/056813

申请日：2017-03-22

Applicant: GLYCOTOPE GMBH

Inventor： GOLETZ, Steffen ,  DANIELCZYK, Antje ,  HART, Felix

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC classification number: C07K16/00 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/3092 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/94

Abstract: The present invention pertains to IgA antibodies having an optimized glycosylation pattern. These IgA antibodies exhibit an increased stability and an extended shelf life. Compositions comprising IgA antibodies having an improved glycosylation pattern and methods for improving the shelf life of IgA antibodies are provided.

Abstract translation: 本发明涉及具有优化的糖基化模式的IgA抗体。 这些IgA抗体表现出增加的稳定性和延长的保质期。 提供了包含具有改善的糖基化模式的IgA抗体的组合物和用于改善IgA抗体保质期的方法。

公开(公告)号：WO2017140845A1

公开(公告)日：2017-08-24

申请号：PCT/EP2017/053616

申请日：2017-02-17

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE MONTPELLIER ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7

Inventor： ROBERT, Bruno ,  MARTINEAU, Pierre ,  COUVINEAU, Alain

IPC: C07K14/575 ,  A61K38/22

CPC classification number: C07K14/575 ,  A61K38/00 ,  A61K47/6811 ,  A61K47/6849 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K2319/00

Abstract: The present invention relates to polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor. In particular, the present invention relates to a polypeptide comprising the amino acid sequence of formula of X20- X21-X22-X23-G-X25-L-X27-X28 wherein: - X20 represents N, D, or K, - X21 represents H, A or Q, - X22 represents A, S, T or G, - X23 represents A, T or G, - X25 represents I or L, - X27 represents T or V and, - X28 represents M, L, V, Y or I.

Abstract translation: 本发明涉及用于制备能够在表达食欲肽受体的细胞中促进凋亡的药物缀合物的多肽。 特别地，本发明涉及包含式X20-X21-X22-X23-G-X25-L-X27-X28的氨基酸序列的多肽，其中：-X20代表N，D或K，-X21代表 H，A或Q，-X 22代表A，S，T或G，-X 23代表A，T或G，-X 25代表I或L，-X 27代表T或V，和-X 28代表M，L，V， Y或我。

公开(公告)号：WO2017137503A1

公开(公告)日：2017-08-17

申请号：PCT/EP2017/052893

申请日：2017-02-09

Applicant: DAIICHI SANKYO EUROPE GMBH ,  DAIICHI SANKYO COMPANY, LIMITED

Inventor： ABRAHAM, Reimar ,  FUKUCHI, Keisuke

IPC: C07K16/28 ,  A61K39/395 ,  A61K31/4412 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K31/44 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2300/00

Abstract: The present invention relates to the medical use of antibodies against the FGF receptor 4 (FGFR4) combined with Sorafenib, in particular for the prevention or treatment of hyperproliferative diseases associated with FGFR expression, overexpression or hyperactivity.

Abstract translation: 本发明涉及与索拉非尼组合的抗FGF受体4（FGFR4）的抗体的医学用途，特别是用于预防或治疗与FGFR表达，过表达或过度活性相关的过度增殖性疾病。 / p>

公开(公告)号：WO2017136820A2

公开(公告)日：2017-08-10

申请号：PCT/US2017/016691

申请日：2017-02-06

Applicant: EPIMAB BIOTHERAPEUTICS, INC. ,  WU, Chengbin

Inventor： WU, Chengbin

IPC: A61K39/395 ,  C07K19/00

CPC classification number: A61K39/395 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/22 ,  C07K16/241 ,  C07K16/244 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/36 ,  C07K2317/14 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/64 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.

Abstract translation: 本发明提供了能够结合两种或更多种抗原或两种或更多种表位的多价和多特异性结合蛋白。 本发明还提供了制备和使用这种多价和多特异性结合蛋白的方法，包括使用这些结合蛋白预防或治疗各种疾病的方法，或体外或体内检测特异性抗原的方法。

公开(公告)号：WO2017134592A1

公开(公告)日：2017-08-10

申请号：PCT/IB2017/050562

申请日：2017-02-02

Applicant: BIOCON LIMITED

Inventor： GOVINDAPPA, Nagaraja ,  MOOLE, Praveen Kumar, Reddy ,  SRINIVASA, Sreesha, P

IPC: A61K47/00 ,  A61K39/44 ,  A61K39/395 ,  C07K16/46

CPC classification number: C07K16/2887 ,  C07K16/2803 ,  C07K16/2863 ,  C07K2317/732 ,  C07K2319/00

Abstract: The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, fusion protein comprises of at least one targeting moiety and at least one immunomodulatory moiety 5 that counteracts the immune tolerance of cancer cells. The present invention provides fusion molecules of Anti-CD20-TGFβRII, Anti-CD20-PD1 and Anti-CD20-TIM3 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.

Abstract translation: 本发明一般涉及产生用于癌症治疗的重组嵌合融合蛋白的领域，更具体地说，融合蛋白包含至少一个靶向部分和至少一个免疫调节部分5 这抵消了癌细胞的免疫耐受性。 本发明提供了抗-CD20-TGFβRII，抗-CD20-PD1和抗-CD20-TIM3的融合分子及其产生方法，其中所述方法降低了生产成本并提高了重组嵌合融合蛋白的同质性。